Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes.

Slides:

Advertisements

Similar presentations

Surgical margins for melanoma in situ

Advertisements

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

A girl with a solitary red bulla

Yul W. Yang, MD, PhD, David J. DiCaudo, MD

Daniel S. Winchester, MD, Thomas L. Hocker, MD, Randall K. Roenigk, MD

Image registration of sequential transparent photographs to localize and detect new versus recurrent tumors in dermatologic and Mohs micrographic surgery

Megan Wood, MD, Tom Raisanen, MD, Ingrid Polcari, MD

Focal nail dystrophy in a cutaneous nerve distribution after trauma

Elana Putterman, BS, Leslie Castelo-Soccio, MD, PhD

High neutrophil-to-lymphocyte ratio before starting anti-programmed cell death 1 immunotherapy predicts poor outcome in patients with metastatic melanoma

John R. Meuleman, MD, William F. Brechue, PhD, Paul S

Pediatric teledermatology: Observations based on 429 consults

Expression of programmed death receptor ligand 1 in melanoma may indicate tumor progression and poor patient survival Junna Oba, MD, PhD, Takeshi Nakahara,

Low plasma coenzyme Q10 levels as an independent prognostic factor for melanoma progression Luigi Rusciani, MD, Ilaria Proietti, MD, Antonio Rusciani,

Melanoma survival in the United States, 1992 to 2005

Design and Multiseries Validation of a Web-Based Gene Expression Assay for Predicting Breast Cancer Recurrence and Patient Survival Ryan K. Van Laar

Validation of the Stage Groupings in the Eighth Edition of the TNM Classification for Lung Cancer Xizhao Sui, MD, Wei Jiang, MD, Haiqing Chen, MD, Fan.

Sara A. Farber, BA, Sara Samimi, MD, Misha Rosenbach, MD

Smoking and risk of psoriasis: A nationwide cohort study

Consensus of Melanoma Gene Expression Subtypes Converges on Biological Entities Martin Lauss, Jeremie Nsengimana, Johan Staaf, Julia Newton-Bishop, Göran.

Methotrexate treatment in patients with a history of cutaneous melanoma and the risk of a consecutive primary melanoma: A national retrospective registry-based.

Treatment of toxic epidermal necrolysis in North America

Heterogeneous spectrum of acral melanoma: A clinicoprognostic study of 213 acral melanomas according to tumor site Hye Rim Moon, MD, Hyun Ji Kang, MD,

Patient and Graft Survival Following Kidney Transplantation in Recipients With Cystinosis: A Cohort Study Rebecca A. Spicer, MBChB, Philip A. Clayton,

Chauncey C. Caldwell, MD, Sami K. Saikaly, MD, Robert P

Reply to: “A note on normality”

The applicability and prognostic value of the TNM classification system for primary cutaneous lymphomas other than mycosis fungoides and Sézary syndrome.

The prognostic impact of microRNA sequence polymorphisms on the recurrence of patients with completely resected non–small cell lung cancer Kyong-Ah Yoon,

Vitamin D deficiency in patients with chronic and acute urticaria: A systematic review and meta-analysis Tsung-Yu Tsai, MD, Yu-Chen Huang, MD Journal.

Successful use of a modified Goeckerman regimen in the treatment of generalized prurigo nodularis Eric Sorenson, AB, Ethan Levin, MD, John Koo, MD, Timothy.

A survey-based study on nail examinations at an American Academy of Dermatology free skin cancer screening Dayoung Ko, BS, Shari R. Lipner, MD, PhD

Influence of diabetes on survival in patients with cystic fibrosis before and after lung transplantation Don Hayes, MD, MS, Alpa V. Patel, MD, Sylvester.

Infectious rash after riding elephants

Robert Kantor, BS, Prarthana Dalal, BS, David Cella, PhD, Jonathan I

Minichromosome maintenance protein expression in benign nevi, dysplastic nevi, melanoma, and cutaneous melanoma metastases Alan S. Boyd, MD, Bashar Shakhtour,

Lip edema Journal of the American Academy of Dermatology

Development and validation of a noninvasive 2-gene molecular assay for cutaneous melanoma Pedram Gerami, MD, Zuxu Yao, PhD, David Polsky, MD, PhD, Burkhard.

Acrylic nail curing UV lamps: High-intensity exposure warrants further research of skin cancer risk Julia Curtis, MD, Paul Tanner, CCA, Cambria Judd,

Predictors of Death, Local Recurrence, and Distant Metastasis in Completely Resected Pathological Stage-I Non–Small-Cell Lung Cancer Jung-Jyh Hung, MD,

Tumor-Infiltrating Foxp3+ Regulatory T Cells are Correlated with Cyclooxygenase-2 Expression and are Associated with Recurrence in Resected Non-small.

National trends in utilization, mortality, and survival after repair of type B aortic dissection in the Medicare population Douglas W. Jones, MD, Philip.

Survival by time of day of hemodialysis: analysis of United States renal data system dialysis morbidity and mortality waves III/IV Kevin C Abbott, MD,

Yuji Tachimori, MD, Hoichi Kato, MD, Hiroshi Watanabe, MD

Assessing Genetic Expression Profiles in Melanoma Diagnosis

Medicaid acceptance among pediatric dermatologists

Identification of high-risk cutaneous melanoma tumors is improved when combining the online American Joint Committee on Cancer Individualized Melanoma.

Use of a prognostic gene expression profile test for T1 cutaneous melanoma: Will it help or harm patients? Michael A. Marchetti, MD, Edmund K. Bartlett,

Increased risks of autoimmune rheumatic diseases in patients with psoriasis: A nationwide population-based study Hyun Jeong Ju, MD, Ki-Jo Kim, MD, PhD,

Role of graft-versus-host disease in the development of secondary skin cancers in hematopoietic stem cell transplant recipients: A meta-analysis Pooja.

Recent dermatology visit is associated with thinner Breslow depth nodular melanomas Erin X. Wei, MD, Lucy Chen, MD, Fangchao Ma, PhD, Jonette Keri, MD,

Christopher T. Cassetty, MD, Andrew F. Alexis, MD, MPH, Jerome L

Hyun Sun Jeon, MD, Mira Choi, MD, Seong Jun Byun, MS, Leejee H

Tsung-Yu Tsai, MD, Yu-Chen Huang, MD

Hazard rates for recurrent and secondary cutaneous melanoma: An analysis of 33,384 patients in the German Central Malignant Melanoma Registry Ulrike.

Tofacitinib therapy for children with severe alopecia areata

Michelle A. Pipitone, MD, Brian Adams, MD, MPH, Anita Sheth, MD, T

Minimal improvements in the global burden of skin disease from 1990 to 2013 Jessica Mounessa, Taylor Braunberger, MD, Cory A. Dunnick, MD, Robert P. Dellavalle,

Descriptive survival study of nail melanoma patients treated with functional surgery versus distal amputation Suelen Montagner, MD, Francisco Aparecido.

Eyebrow transplantation: Alternative body sites as a donor source

Gaps in pain management in dermatology: A needs assessment from Canada

Numerous hyperpigmented macules of the oral mucosa

Stage III Thymic Epithelial Neoplasms are Not Homogeneous with Regard to Clinical, Pathological, and Prognostic Features Min-Woong Kang, MD, PhD, Eung-Sirk.

Brittany G. Craiglow, MD, Brett A. King, MD, PhD

Fig. 1. Classification of the Kaplan-Meier curves and Cox survival estimates for the OS of patients using the pSPC in Cohort_C and in the overall population.

Comparison of tumor staging systems for cutaneous squamous cell carcinoma in patients with chronic lymphocytic leukemia Jacob J. Inda, MD, Brian F. Kabat,

Axillary-to-carotid artery bypass grafting for symptomatic severe common carotid artery occlusive disease Joseph P. Archie, PhD, MD Journal of Vascular.

Orit Kaidar-Person, MD, Ayelet Eran, MD, Gil Bar-Sela, MD

Stuart M. Goldsmith, MD, Armand B. Cognetta, MD

Presentation transcript:

Identification of patients at risk of metastasis using a prognostic 31-gene expression profile in subpopulations of melanoma patients with favorable outcomes by standard criteria Brian R. Gastman, MD, Pedram Gerami, MD, Sarah J. Kurley, PhD, Robert W. Cook, PhD, Sancy Leachman, MD, PhD, John T. Vetto, MD Journal of the American Academy of Dermatology Volume 80, Issue 1, Pages 149-157.e4 (January 2019) DOI: 10.1016/j.jaad.2018.07.028 Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 1 The 31-gene expression profile (31-GEP) class and correlated survival outcomes of the cohort of 690 patients with cutaneous melanoma (CM). Recurrence-free survival (RFS) (A), distant metastasis-free survival (DMFS) (B), and melanoma-specific survival (MSS) (C) rates for 690 patients were obtained by using molecular 31-GEP subclassification in Kaplan-Meier analysis. The tables below the curves show the number of patients with each 31-GEP class, 5-year survival rates for the outcome with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. P values were determined by the log-rank test. Journal of the American Academy of Dermatology 2019 80, 149-157.e4DOI: (10.1016/j.jaad.2018.07.028) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 2 Kaplan-Meier analysis of sentinel lymph node–negative (SLN neg) patients and 31-gene expression panel (31-GEP) class in the cohort of 690 patients with cutaneous melanoma (CM). Recurrence-free survival (RFS) (A), distant metastasis-free survival (DMFS) (B), and melanoma-specific survival (MSS) (C) rates for patients with negative SLN biopsy results (n = 259) using molecular 31-GEP subclassification in Kaplan-Meier analysis. The tables below the curves show the number of patients with each 31-GEP class, 5-year survival rates for the outcome with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. P values determined by the log-rank test. Journal of the American Academy of Dermatology 2019 80, 149-157.e4DOI: (10.1016/j.jaad.2018.07.028) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Fig 3 Survival outcomes for patients with stage I and IIA cutaneous melanoma (CM) with molecular classification by the 31-gene expression panel (31-GEP) test. Recurrence-free survival (RFS) (A), distant metastasis-free survival (DMFS) (B), and melanoma-specific survival (MSS) (C) rates for patients with stage I and IIA disease (n = 393) with use of molecular 31-GEP subclassification in Kaplan-Meier analysis. The tables below the curves show the number of patients with each 31-GEP class, 5-year survival rates for the outcome with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. Journal of the American Academy of Dermatology 2019 80, 149-157.e4DOI: (10.1016/j.jaad.2018.07.028) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions

Supplemental Fig 1 Survival outcomes for patients with cutaneous melanoma (CM) with T1 (≤1 mm) tumors with use of molecular classification by the 31-gene expression panel (31-GEP) test. Recurrence-free survival (RFS) (A) and distant metastasis-free survival (DMFS) (B) rates for patients with tumors with a thickness of 1 mm or less (n = 281) with use of molecular 31-GEP subclassification in Kaplan-Meier analysis. The table below the curve shows number of patients with each 31-GEP class, 5-year survival rates with 95% confidence intervals (CIs), and number of events with percentages of the class experiencing the event. P values were determined by the log-rank test. Journal of the American Academy of Dermatology 2019 80, 149-157.e4DOI: (10.1016/j.jaad.2018.07.028) Copyright © 2018 American Academy of Dermatology, Inc. Terms and Conditions